| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Integrative Physiology |
From the Institut für Pharmakologie und Klinische Pharmakologie (B.H.R., M.B., K.S.), UniversitätsKlinikum Düsseldorf, Heinrich-Heine-Universität, Düsseldorf; and Zentrum für Vaskuläre Biologie und Medizin Erfurt (E.B.), Friedrich-Schiller-Universität Jena, Germany.
Correspondence to Karsten Schrör, Institut für Pharmakologie und Klinische Pharmakologie, Moorenstr. 5, D-40225 Düsseldorf, Germany. E-mail kschroer{at}uni-duesseldorf.de
Promatrix metalloproteinase-2 (proMMP-2) is expressed in vascular smooth muscle cells (SMCs). We report that activated coagulation factor X (FXa) induces the release of MMP-2 (65 kDa) from human SMCs. In addition, FXa cleaves proMMP-2 (72 kDa) into MMP-2. ProMMP-2 and MMP-2 were determined by gelatin zymography. MMP-2 was generated in conditioned medium containing proMMP-2 in a concentration-dependent fashion by FXa (3 to 100 nmol/L). FX at concentrations up to 300 nmol/L was ineffective. The conversion of proMMP-2 to MMP-2 was inhibited by a selective FXa inhibitor (DX-9065a) at 3 to 10 µmol/L. There was a concentration-dependent induction of an intermediate MMP-2 form (68 kDa) in lysates of FXa-treated cells. This indicates that cellular mechanisms are involved in FXa-induced conversion of proMMP-2. As a possible biological consequence of MMP-2 activation by FXa, DNA synthesis and matrix invasion of SMCs were determined. Both were stimulated by FXa and inhibited by the selective FXa inhibitor DX-9065a and the MMP inhibitor GM 6001 but not by hirudin or aprotinin. It is concluded that stimulation of SMCs by FXa increases the levels of MMP-2 in the extracellular space and that two different mechanisms are involved: release of active MMP-2 and cleavage of secreted proMMP-2. Both might contribute to the mitogenic potency of FXa and FXa-stimulated matrix invasion of SMCs.
Key Words: matrix metalloproteinase-2 factor Xa vascular smooth muscle cells extracellular matrix invasion mitogenesis
This article has been cited by other articles:
![]() |
A. C. Rosenkranz, B. H. Rauch, K. Freidel, and K. Schror Regulation of protease-activated receptor-1 by vasodilatory prostaglandins via NFAT Cardiovasc Res, September 1, 2009; 83(4): 778 - 784. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.-H. Koo, M. Y. Park, O.-H. Jeon, and D.-S. Kim Regulatory Mechanism of Matrix Metalloprotease-2 Enzymatic Activity by Factor Xa and Thrombin J. Biol. Chem., August 28, 2009; 284(35): 23375 - 23385. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Kandasamy, A. K. Chow, M. A.M. Ali, and R. Schulz Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix Cardiovasc Res, August 20, 2009; (2009) cvp268v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pape, B. H. Rauch, A. C. Rosenkranz, G. Kaber, and K. Schror Transcriptional Inhibition of Protease-Activated Receptor-1 Expression by Prostacyclin in Human Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, March 1, 2008; 28(3): 534 - 540. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Bhattacharjee, J. Ahamed, R. Pawlinski, C. Liu, N. Mackman, W. Ruf, and T. S. Edgington Factor Xa Binding to Annexin 2 Mediates Signal Transduction via Protease-Activated Receptor 1 Circ. Res., February 29, 2008; 102(4): 457 - 464. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. H. Rauch, G. A. Scholz, D. Baumgartel-Allekotte, P. Censarek, J. W. Fischer, A.-A. Weber, and K. Schror Cholesterol Enhances Thrombin-Induced Release of Fibroblast Growth Factor-2 in Human Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): e20 - e25. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kodali, M. Hajjou, A. B. Berman, M. B. Bansal, S. Zhang, J. J. Pan, and A. D. Schecter Chemokines induce matrix metalloproteinase-2 through activation of epidermal growth factor receptor in arterial smooth muscle cells Cardiovasc Res, February 15, 2006; 69(3): 706 - 715. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Newby Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque Rupture Physiol Rev, January 1, 2005; 85(1): 1 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. W. Kopp, T. Holzenbein, S. Steiner, R. Marculescu, H. Bergmeister, D. Seidinger, I. Mosberger, C. Kaun, M. Cejna, R. Horvat, et al. Inhibition of restenosis by tissue factor pathway inhibitor: in vivo and in vitro evidence for suppressed monocyte chemoattraction and reduced gelatinolytic activity Blood, March 1, 2004; 103(5): 1653 - 1661. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |